Genetic Signatures Dirección

Dirección controles de criterios 2/4

El CEO de Genetic Signatures' es John Melki , nombrado en Jan 2011, tiene una permanencia de 13.25 años. compensación anual total es A$596.94K, compuesta por 65.5% salario y 34.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.68% de las acciones de la empresa, por valor de A$851.05K. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 8.6 años, respectivamente.

Información clave

John Melki

Chief Executive Officer (CEO)

AU$596.9k

Compensación total

Porcentaje del salario del CEO	65.5%
Permanencia del CEO	13.3yrs
Participación del CEO	0.7%
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	8.7yrs

Actualizaciones recientes de la dirección

Recent updates

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Melki en comparación con los beneficios de Genetic Signatures?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$18m
Sep 30 2023	n/a	n/a	-AU$16m
Jun 30 2023	AU$597k	AU$391k	-AU$14m
Mar 31 2023	n/a	n/a	-AU$11m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$613k	AU$367k	AU$3m
Mar 31 2022	n/a	n/a	AU$3m
Dec 31 2021	n/a	n/a	AU$2m
Sep 30 2021	n/a	n/a	AU$2m
Jun 30 2021	AU$625k	AU$355k	AU$2m
Mar 31 2021	n/a	n/a	AU$3m
Dec 31 2020	n/a	n/a	AU$5m
Sep 30 2020	n/a	n/a	AU$1m
Jun 30 2020	AU$564k	AU$308k	-AU$2m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$390k	AU$292k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$376k	AU$275k	-AU$3m
Mar 31 2018	n/a	n/a	-AU$3m
Dec 31 2017	n/a	n/a	-AU$3m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$386k	AU$256k	-AU$3m

Compensación vs. Mercado: La compensación total de John($USD385.00K) está por encima de la media de empresas de tamaño similar en el mercado Australian ($USD289.12K).

Compensación vs. Ingresos: La compensación de John ha sido consistente con los resultados de la empresa en el último año.

CEO

John Melki

13.3yrs

Permanencia

AU$596,939

Compensación

Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Principal Advisor. Dr. Melki has been...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Melki	MD, CEO & Executive Director	13.3yrs	AU$596.94k	0.68% A$ 888.9k
Michael Aicher	Executive Director of US Operations & Executive Director	10.3yrs	AU$178.42k	0.35% A$ 455.3k
Christopher Abbott	Founder & Chairman Emeritus	no data	sin datos	sin datos
Karl Pechmann	CFO, COO & Company Secretary	less than a year	sin datos	sin datos
Douglas Millar	Chief Scientific Officer	23.3yrs	AU$308.55k	sin datos
Rebecca Abbatantuono	Global Head of People & Culture	less than a year	sin datos	sin datos
Neralie Coulston	Global Head of Regulatory Affairs	1.5yrs	sin datos	sin datos
Jackson Jones	Chief Commercial Officer	1.5yrs	sin datos	sin datos

1.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de GSS no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Melki	MD, CEO & Executive Director	10.1yrs	AU$596.94k	0.68% A$ 888.9k
Michael Aicher	Executive Director of US Operations & Executive Director	10.3yrs	AU$178.42k	0.35% A$ 455.3k
Christopher Abbott	Founder & Chairman Emeritus	no data	sin datos	sin datos
Anthony Radford	Non-Independent Non-Executive Director	8.7yrs	AU$72.42k	0.15% A$ 194.6k
Caroline Waldron	Non-Executive Director	2yrs	AU$72.42k	0.010% A$ 13.5k
Nickolaos Samaras	Independent Non-Executive Chairman	16.3yrs	AU$129.84k	1.25% A$ 1.6m
Stéphane Chatonsky	Director	less than a year	sin datos	0.087% A$ 113.9k
Neil Gunn	Non-Executive Director	3.1yrs	AU$189.76k	sin datos

8.7yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de GSS se considera experimentada (8.6 años de antigüedad promedio).

Genetic Signatures Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Director recently bought AU$59k worth of stock

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Less than half of directors are independent

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Recent updates

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad